Canagliflozin (Invokana) - SGLT-2 Inhibitors
Document Details
Uploaded by SkillfulOnyx4668
Chamberlain University
Tags
Related
- CAPÍTULO 404 Diabetes mellitus Tratamiento PDF
- Recommendations for Type 2 Diabetes Treatment PDF
- Non-Insulin Treatment of Type 2 Diabetes PDF
- Diabetes Handout 2024: Products Used in the Treatment of Diabetes Mellitus
- Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors PDF
- Oral Agents for Diabetes Part 7 PDF
Summary
This document describes the prototype drug canagliflozin (Invokana), a type of SGLT-2 inhibitor used in diabetes treatment. Canagliflozin works by lowering blood glucose levels in adults with type 2 diabetes, and it can be added to existing treatment regimens. It often results in weight loss due to its unique feature of glucose excretion in urine.
Full Transcript
**Prototype: canagliflozin (Invokana) ** - **Category: **Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors (Oral Hypoglycemic Agent) - **Primary Function: **SGLT-2 inhibitors lower blood glucose levels in adults with type 2 diabetes by promoting glucose excretion in the urine. Th...
**Prototype: canagliflozin (Invokana) ** - **Category: **Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors (Oral Hypoglycemic Agent) - **Primary Function: **SGLT-2 inhibitors lower blood glucose levels in adults with type 2 diabetes by promoting glucose excretion in the urine. They can also be added to the treatment regimen of clients who are overweight or have a risk of hypoglycemia. - **Unique Features: **Glycosuria from SGLT-2 inhibitors can also cause weight loss. - **Example drugs in this class**: - Bexaglifloxin (Brenzavvy™) - Canagliflozin (Invokana®) - Dapagliflozin (Farxiga®) - Empagliflozin (Jardiance®) - Ertugliflozin (Steglatro®)
